Jasper Therapeutics Inc.
JSPR
We are a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria ( CSU ), Chronic Inducible Urticaria ( CIndU ) and asthma and we continue to consider additional indications in mast cell driven diseases for potential future development. We have also historically explored development programs in di…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$157M
▼ -6.4% YoY
Op. Margin
–
ROIC
-5040.64%
▼ -109.2pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$49M
▼ -23.3% YoY
Net Debt
-$135M
Net Cash Position
Cash & Equiv.
$135M
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with JSPR
Jasper Therapeutics (JSPR) in two numbers
Questions about Jasper Therapeutics
Does Jasper Therapeutics (JSPR) pay a dividend?
No. Jasper Therapeutics (JSPR) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 10 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in JSPR's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing JSPR
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.